IMF Videos Search Content For Healthcare Professional (166) Healthcare Provider (165) Care Partner (128) Patient (128) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (261) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance MagnetisMM-9: Efficacy and Safety of Step-up Priming Doses and Longer Dosing Intervals of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma February 19, 2025 ASH Lisaftoclax Combined with Novel Therapies in Relapsed/Refractory Multiple Myeloma and Amyloidosis February 14, 2025 ASH Belantamab Mafodotin with VRd in ASCT-Ineligible Newly Diagnosed Multiple Myeloma: DREAMM-9 Study Findings February 13, 2025 ASH Patient-Centric Myeloma Research at ASH 2024: Quality of Life, Exercise, Nutrition & More February 11, 2025 ASH Myeloma Research: Late Relapse, CAR T-Cell Therapy & Bispecific Antibodies at ASH 2024 February 11, 2025 ASH Belantamab & CAR T-Cell Therapy: Key ASH 2024 Updates on Early Myeloma Relapse February 6, 2025 ASH Frontline Therapy Advances for Multiple Myeloma Patients | ASH 2024 Insights for Patients January 30, 2025 ASH MRD Progression in Newly Diagnosed MM: What Happens After Quad Therapy and Stem Cell Transplant? January 28, 2025 ASH ISB2001 A Groundbreaking Trispecific Antibody Shows Promise for Advanced Multiple Myeloma Patients January 28, 2025 ASH Mezigdomide: New Drug Combination Trial Results for Multiple Myeloma Treatment January 27, 2025 ASH New Standard of Care for High-Risk Smoldering Multiple Myeloma: Insights from ASH 2024 January 23, 2025 ASH Selinexor Pom Dex (SPd) Combo Shows Promise: New Treatment Option for Relapsed Multiple Myeloma January 21, 2025 ASH Load More
